


IFW

File No. 15493-2US IC/MG/mm

Québec, Canada
April 25, 2005



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Marc BEAUREGARD
Serial No: 10/776,180
Filed: February 12, 2004
Title: METHOD OF MUTAGENIC CHAIN REACTION
Group Art Unit: Unknown
Examiner: Unknown
Agent of Record: Isabelle Chabot Tel.: (418) 640-5174

INFORMATION DISCLOSURE STATEMENT
PRIOR TO FIRST OFFICE ACTION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the duty of disclosure under 37 CFR 1.56, copies of the references listed on the attached PTO Form 1449 are submitted herewith.

The Examiner is kindly requested to consider these references during the examination of the above-identified application, making the references of record, and to return an initialed copy of the PTO-1449 Form to the below-signed agent.

In accordance with 37 CFR 1.97(h), the submission of the present information is not to be construed as an admission that such information is, or is considered to be material to patentability.

Commissioner for Patents

Attorney Docket: 15493-2US IC/MG/mm

The Director is hereby authorized to charge any fees which may be required or credit any overpayment, to Deposit Account Number 19-5113.

Respectfully submitted,



Isabelle Chabot
Registration No. 55,764

Date: April 25, 2005

OGILVY RENAULT
CUSTOMER 020988
1981 McGill College Avenue, Suite 1600
Montréal, Quebec, CANADA H3A 2Y3

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



Substitute for form 1449PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **1** of **3****Complete if Known**

Application Number	10/776,180
Filing Date	02/12/2004
First Named Inventor	Marc Beauregard
Art Unit	
Examiner Name	
Attorney Docket Number	15493-2US MG/al

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	A1	US-4,683,202	07-28-1987	Mullis	
		US-4,683,195	07-28-1987	Mullis et al.	
		US-4,800,159	01-24-1989	Mullis et al.	
		US-4,965,188	10-23-1990	Mullis et al.	
		US-5,512,462	04-30-1996	Suzanne Cheng	
		US-5,612,473	03-18-1997	Wu et al.	
		US-5,602,756	02-11-1997	Atwood et al.	
		US-5,538,871	07-23-1996	Nuovo et al.	
		US-5,475,610	12-12-1995	Atwood et al.	
		US-6,448,048	09-10-2002	Tomono et al.	
		US-6,489,145	12-03-2002	Short	
		US-6,506,602	01-14-2003	Stemmer	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	†
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

DOCSQUE: 34494. If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/776,180		
		Filing Date	02/12/2004		
		First Named Inventor	Marc Beauregard		
		Art Unit			
		Examiner Name			
Sheet	2	of	3	Attorney Docket Number	15493-2US MG/al

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	B1	Stemmer, (1994), Proc. Natl. Acad. Sci. USA, <u>91</u> :10747-10751	
	B2	Cox, (1976), Annu. Rev. Genet. <u>10</u> :135-156	
	B3	Shortle, (1983), Methods Enzymol., <u>100</u> :457-468	
	B4	Mott et al., (1984) Nucleic Acids Res., <u>12</u> :4139-4152	
	B5	Chiang L. et al., (1993), PCR Methods Applic., <u>2</u> :210-217	
	B6	Leung, D.W. et al., (1989) Technique, <u>1</u> :11-15	
	B7	Chao K.M. (1992), Comput. Appl. Biosci., 8:481-487	
	B8	Cadwell and Joyce, (1992) PCR methods appl. <u>2</u> :28-33	
	B9	Vartanian et al., (1996), Nucleic Acids Res., <u>14</u> :2627-2631	
	B10	New England Biolabs Inc (2002-2003)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

DOCSQUE: 344271 If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/776,180
				Filing Date	02/12/2004
				First Named Inventor	Marc Beauregard
				Art Unit	
				Examiner Name	
Sheet	3	of	3	Attorney Docket Number	15493-2US MG/al

	B11	Grundy et al., Crystallization and Stabilization of MB-1, a de novo designed protein for optimized feeding technology, Journal of Biotechnology 63 (1998) 9-15.	
	B12	Fromant et al., Direct Random Mutagenesis of Gene-Sized DNA Fragments Using Polymerase Chain Reaction, Analytical Biochemistry 224, 347-353 (1995).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.**

DOCSQUE: 3442711 If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.